- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patent holdings for IPC class C07K 16/00
Total number of patents in this class: 11441
10-year publication summary
|
876
|
814
|
881
|
827
|
786
|
753
|
627
|
489
|
444
|
340
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4810 |
289 |
| Amgen Inc. | 4467 |
258 |
| Genentech, Inc. | 4132 |
191 |
| Chugai Seiyaku Kabushiki Kaisha | 1426 |
164 |
| F. Hoffmann-La Roche AG | 7798 |
151 |
| Hoffmann-La Roche Inc. | 3841 |
149 |
| The Regents of the University of California | 20902 |
114 |
| Novartis AG | 10169 |
96 |
| Abbvie Inc. | 1800 |
92 |
| Xencor, Inc. | 409 |
76 |
| Ablynx N.V. | 425 |
72 |
| Janssen Biotech, Inc. | 1794 |
71 |
| Bristol-myers Squibb Company | 4757 |
70 |
| Sanofi | 4326 |
64 |
| Pfizer Inc. | 3418 |
62 |
| Cytiva BioProcess R&D AB | 327 |
59 |
| MedImmune, LLC | 496 |
58 |
| Zymeworks Inc. | 258 |
54 |
| Daiichi Sankyo Company, Limited | 1890 |
52 |
| Genzyme Corporation | 1381 |
51 |
| Other owners | 9248 |